Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL

EP: 1.Navigating Frontline Treatment Options in CLL

EP: 2.Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting

EP: 3.Expert Perspectives on Extended Follow-Up Data from ALPINE

Now Viewing

EP: 4.Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL

EP: 5.Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection

EP: 6.Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL

EP: 7.Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL

This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.

Ujjani and Furman discuss the ELEVATE-RR study, comparing acalabrutinib and ibrutinib in patients with high-risk chronic lymphocytic leukemia. With around 40% of patients having a TP53 mutation, acalabrutinib shows a median progression-free survival of about 38 months, highlighting its attractiveness in relapsed/refractory (R/R) cases.

Comparing acalabrutinib to zanubrutinib directly is cautioned against due to differing patient populations. Ujjani anticipates continued progression-free survival benefits in the ALPINE study and minimal surprises in the ELEVATE-RR study.

The conversation delves into the nature of continuous therapy versus fixed duration, particularly addressing infection risks. Furman suggests limiting therapy duration may decrease infection risks, emphasizing the importance of time off therapy and its potential advantages over continuous Bruton tyrosine kinase inhibition in managing infection risks.

This summary was AI-generated and reviewed by OncLive^® editorial staff.